compound introduction
AZD3229 是一种突变型酪氨酸激酶受体抑制剂，可用于胃肠道间质瘤的研究 Information AZD3229 is a potent, pan-Kit (c-Kit) mutantinhibitor with potent single digit nM growth inhibition against a diverse panel of mutant Kit (c-Kit) driven Ba/F3 cell lines (GI50=1-50 nM), with good margin to KDR-driven effects. It also inhibitsPDGFR mutants(Tel-PDGFRα, Tel-PDGFRβ, V561D/D842V). Targets Kit ; PDGFRα ; PDGFRβ In vivo In preclinical species, bioavailability is high and clearance low across all of mouse, rat, and dog. Volume of distribution is low consistent with the neutral structure. In in vivo models using Ba/F3 cell lines, AZD3229 at a dose of 20 mg/kg b.i.d induces tumor volume regression more effectively than regorafenib at a dose of 100 mg/kg q.d and imatinib.
